Kylonova (Xiamen) Biopharma Co., Ltd.

Kylonova (Xiamen) Biopharma Co., Ltd. is mainly engaged in the research and development of new drugs and delivery platforms for siRNA (small interfering nucleic acids). The company has established three delivery platforms for siRNA with proprietary technologies, including Nano-Lipid Particle(NPDP) , Multi-Valent Import platform (MVIP) and Lipid-Coupling Delivery platform(LCDP). The technologies and quality standards of three delivery platforms are on the cutting-edge in the same fields, and can be scaled-up and manufactured for commercialization. Kylonova also performs solid phase oligonucleotide synthesis and DNA and RNA API production and can supply a contract manufacture.